NCT04687761 2026-05-13Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years OldPETHEMA FoundationPhase 1/2 Completed113 enrolled